Tecnis multifocal safe and effective in hyperopia and presbyopia

Article

The Tecnis multifocal intraocular lens (MIOL) is safe and efficacious for refractive lensectomy in hyperopia and presbyopia, according to Frank Goes, Belgium.

The Tecnis multifocal intraocular lens (MIOL) is safe and efficacious for refractive lensectomy in hyperopia and presbyopia, according to Frank Goes, Belgium.

At a private outpatient centre in Antwerp, Belgium, 94 presbyopic hyperopic eyes of 47 subjects were implanted with the Tecnis MIOL. Outcomes were recorded at six months from baseline.

The lens demonstrated two clearly defined focal points and MTF results, independent of pupil size. Uncorrected visual acuity (UCVA) improved from 20/100 preoperatively to 20/23 postoperatively. Best corrected visual acuity (BCVA) improved from 20/25 to 20/20. All but four eyes could read J1 monocular with eventual distance correction and 44 out of the 47 subjects could read J3 at intermediate PC distance (22 inches) with eventual distance correction. No eyes lost any lines of vision and 44 subjects were completely spectacle free. A questionnaire found that the satisfaction degree was either excellent (39 patients; 83%) or good (8 patients; 17%).

Goes concluded that the Tecnis lens is able to offer good visual performance, independent of pupil size, as well as being both safe and efficient in this patient population.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.